ES2173027A2 - Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular. - Google Patents

Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular.

Info

Publication number
ES2173027A2
ES2173027A2 ES200001670A ES200001670A ES2173027A2 ES 2173027 A2 ES2173027 A2 ES 2173027A2 ES 200001670 A ES200001670 A ES 200001670A ES 200001670 A ES200001670 A ES 200001670A ES 2173027 A2 ES2173027 A2 ES 2173027A2
Authority
ES
Spain
Prior art keywords
glaucoma
treatment
ocular hypertension
nucleotides
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES200001670A
Other languages
English (en)
Other versions
ES2173027B2 (es
ES2173027R (es
Inventor
Just Jesus Pintor
Cerda Asuncion Peral
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universidad Complutense de Madrid
Original Assignee
Universidad Complutense de Madrid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universidad Complutense de Madrid filed Critical Universidad Complutense de Madrid
Priority to ES200001670A priority Critical patent/ES2173027B2/es
Priority to PCT/ES2001/000271 priority patent/WO2002007737A1/es
Priority to AU2001270642A priority patent/AU2001270642A1/en
Publication of ES2173027A2 publication Critical patent/ES2173027A2/es
Publication of ES2173027R publication Critical patent/ES2173027R/es
Application granted granted Critical
Publication of ES2173027B2 publication Critical patent/ES2173027B2/es
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Método para el tratamiento del glaucoma y la hipertensión ocular mediante la administración de nucleótidos. La presente invención describe el uso de análogos comerciales del ATP con sustituciones metilén, L-bg-metilen adenosina 5''-trifosfato, imido, D-bg-imido adenosina 5''-trifosfato, así como la sustancia natural adenosina 5'' tetrafosfato Ap4, para el tratamiento del glaucoma y de la hipertensión ocular.
ES200001670A 2000-07-06 2000-07-06 Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular. Expired - Fee Related ES2173027B2 (es)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES200001670A ES2173027B2 (es) 2000-07-06 2000-07-06 Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular.
PCT/ES2001/000271 WO2002007737A1 (es) 2000-07-06 2001-07-06 Metodo para el tratamiento del glaucoma y la hipertension ocular mediante la administracion de nucleotidos
AU2001270642A AU2001270642A1 (en) 2000-07-06 2001-07-06 Method for the treatment of glaucoma and ocular hypertension by administering nucleotides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200001670A ES2173027B2 (es) 2000-07-06 2000-07-06 Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular.

Publications (3)

Publication Number Publication Date
ES2173027A2 true ES2173027A2 (es) 2002-10-01
ES2173027R ES2173027R (es) 2002-10-16
ES2173027B2 ES2173027B2 (es) 2005-12-16

Family

ID=8494145

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200001670A Expired - Fee Related ES2173027B2 (es) 2000-07-06 2000-07-06 Uso de nucleotidos en el tratamiento del glaucoma y la hipertension ocular.

Country Status (3)

Country Link
AU (1) AU2001270642A1 (es)
ES (1) ES2173027B2 (es)
WO (1) WO2002007737A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084128B2 (en) * 2002-01-18 2006-08-01 Inspire Pharmaceuticals, Inc. Method for reducing intraocular pressure
WO2011077435A1 (en) * 2009-12-22 2011-06-30 Bar-Ilan University Compositions and methods for reducing intraocular pressure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869468A (en) * 1994-04-04 1999-02-09 Freeman; William R. Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs
WO2000012098A1 (en) * 1998-09-01 2000-03-09 Yamasa Corporation Medicinal compositions for treating eye diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5869468A (en) * 1994-04-04 1999-02-09 Freeman; William R. Treatment of conditions of abnormally increased intraocular pressure by administration of phosphonylmethoxyalkyl nucleoside analogs and related nucleoside analogs
WO2000012098A1 (en) * 1998-09-01 2000-03-09 Yamasa Corporation Medicinal compositions for treating eye diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GHIARDI, G.J. et al. "The purine nucleoside adenosine in retinal ischemia-reperfusion injury". VISION RESEARCH, Vol. 39, 1999, paginas 2519-2535, resumen y conclusiones. *
PINTOR, J. et al. "Effect of ATP and adeline nucleotides on intraocular pressure in New Zeland rabbits". INVEST. OPHTALMOL. VIS. SCI., Vol. 41, no 4, 15 de marzo de 2000, B 715. *

Also Published As

Publication number Publication date
ES2173027B2 (es) 2005-12-16
WO2002007737A1 (es) 2002-01-31
AU2001270642A1 (en) 2002-02-05
ES2173027R (es) 2002-10-16
WO2002007737B1 (es) 2002-07-18

Similar Documents

Publication Publication Date Title
PH12022553530A1 (en) 1'-cyano nucleoside analogs and uses thereof
EA200600190A1 (ru) Производные пиримидин-2,4-диона в качестве антагонистов рецептора гонадотропин-высвобождающего гормона
EA200100298A1 (ru) ФАРМАЦЕВТИЧЕСКИЕ ПРЕПАРАТЫ С РЕГУЛИРУЕМЫМ ВЫСВОБОЖДЕНИЕМ, СОДЕРЖАЩИЕ ИНГИБИТОР cGMP-ФОСФОДИЭСТЕРАЗЫ-5
UY24560A1 (es) Derivados arilos de la pirimidina útiles como antagonistas 5ht2b selectivos
ES2184705T3 (es) 4-oxo-4,7-dihidro-tieno(2,3-b)piridina-5-carboxamidas como agentes antivirales.
AR022860A1 (es) Derivados de camptotecina que poseen actividad antitumoral
BR9711444A (pt) Derivados de adenosina substituìdos por heterocìclico n6.
CY1105931T1 (el) Χρηση ενος αγωνιστη/ανταγωνιστη οιστρογονου για την αντιμετωπιση γυναικειας σεξουαλικης δυσλειτουργιας
EA200400735A1 (ru) 3-β-D-РИБОФУРАНОЗИЛТИАЗОЛО[4,5-d]ПИРИМИДИННУКЛЕОЗИДЫ И ИХ ПРИМЕНЕНИЯ
EA200601160A1 (ru) 2,6-бисгетероарил-4-аминопиримидины в качестве антагонистов аденозиновых рецепторов
CR10582A (es) Metodos para tratar canceres usando formas poliformicas de 3-(-4-amino-1,3, dihidro-isoindol-2-il)-piperidina-2,6 dione (divisional exp. 8146)
ES2175079T3 (es) Derivados de indol utiles como inhibidores de cgmp-pde.
EA199700203A1 (ru) Синергические комбинации зидовудина, 1592u89 и 3тс или ftc
ECSP088324A (es) 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
PE20001225A1 (es) Derivados de adenina
EA200201291A1 (ru) Производные пурина
UY28150A1 (es) Agentes terapeuticos
DK1171137T3 (da) Anvendelse af triacetyluridin til behandling af mitochondriale lidelser
AR023966A1 (es) Una composicion farmaceutica para la prevencion y/o el tratamiento de la enfermedad de parkinson y los sintomas concomitantes de la misma, y el uso de unantagonista dual receptor de adenosina a1 a2a para preparar dicha composicion
CY1109808T1 (el) Αρυλινδενο-πυριδινες και αρυλινδενο-πυριμιδινες και η χρηση τους ως ανταγωνιστων των υποδοχεων αδενοσινης α2α
BRPI0412327A (pt) derivados de pirimidina-2,4-diona como antagonistas de receptor de hormÈnio liberador de gonadotropina
NO20020931L (no) Pyrrolo[2,3-d]pyrimidin-nukleosid-analoger
BR0314195A (pt) Derivados de piridina substituìda como agentes antitumorais
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas

Legal Events

Date Code Title Description
EC2A Search report published

Ref document number: 20021019

Effective date: 20021019

FG2A Definitive protection

Ref document number: 2173027B2

Country of ref document: ES

FD2A Announcement of lapse in spain

Effective date: 20201026